Media Thread, page-11743

Hi Dhm

As @topfeeder has just said - all shareholders would be rich indeed if CF33 was already proven to kill cancer across all the NCI60 in humans.

The NCI60 studies were "in vitro" - Petri dish.

The next step was animal studies - using mice. I believe they have done animal studies trialling human tumour xenografts in mice of: Pancreatic; Colon; Lung; Triple Neg Breast Cancer. CF33 was effective against them all.

More recently they have also shown effectiveness in mice for intra-peritoneal metastatic gastric cancers.

The first human trials are now in progress - the MAST study (Vaxinia variant) against "any solid cancer type" and also a small study (at City of Hope only) of the Check-vacc version against Triple Negative BC only (that study is being run by City of Hope, not by IMU).

To add to @topfeeder 's second comment: In data released so far - which is only for low dose and mid dose range patients - they have had one complete response (in a Bile Duct cancer patient), 2 partial responses ( in Melanoma). 53% of the IV administered patients achieved "Stable Disease" - ie their cancer stopped progressing. 47% of the Intra-tumoural injection patients saw their cancer burden shrink.

Source: https://investorhub.imugene.com/announcements/6162912

I would stress again that these results are only for patients who received Vaxinia at low or mid level dose ranges. They are now dosing at much higher levels, and we await the results of that.

Cheers

Dave

PS @AK78 - it was 86% of the patients with gastro-intestinal type cancers who saw a "clinical effect" of stable disease or better. 6 stable disease, one complete response and one progressive disease.